Simulations Plus, Inc. (Nasdaq: SLP) ("Simulations Plus" or the "Company"), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced ...

Simulations Plus Inc (NASDAQ:SLP) is among the best medical AI stocks to buy now. On March 26, Simulations Plus announced ...

The healthcare tech company posted its latest set of quarterly earnings.

Simulations Plus (SLP) came out with quarterly earnings of $0.35 per share, beating the Zacks Consensus Estimate of $0.27 per share. This compares to earnings of $0.31 per share a year ago. These ...

Fiscal 2026 revenue guidance is maintained at $79 million to $82 million, reflecting a cautious approach despite strong first ...

A “Validated” column in the DDI perpetrator table to clearly identify the values that have been validated by our DDI experts for use in simulations Dr. Michael Bolger, Founding Scientist of Simulation ...

Simulations Plus Inc. SLP) on Thursday reported earnings of $4.5 million in its fiscal second quarter. The Research Triangle Park, North Carolina-based company said it had profit of 22 cents per share ...

Simulations Plus is benefiting from the growing use of computational tools in drug discovery, which would be boosted by the FDA Modernization Act 2.0. The biosimulation market is highly fragmented and ...

Simulations Plus remains a Hold as business improvement is insufficient to warrant a Buy, despite stabilization post-earnings ...

Simulations Plus, Inc.SLP was a big mover last session, as the company saw its shares rise nearly 6% on the day. Shares gained after the company reported higher earnings and revenues for the third ...

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemical, and consumer goods ...